Preserving the Promise of Cancer Immunotherapy

Preserving the Promise of Cancer Immunotherapy



Rarely does the biopharma industry see anything like the explosion of activity that is immuno-oncology today. There are currently thousands of agents in development, and millions of possible combinations, which need to be tested if we are to successfully treat most cancers. Massive investments are at stake, enormous acquisitions are underway, and there are limited numbers of patients available to participate in trials. How do we keep the promise of immuno-oncology from jumping off the rails?

Custom Author Text

Louise Perkins
Chief Science Officer, Melanoma Research Alliance

Pablo Legorreta
Founder and CEO, Royalty Pharma

Johanna Mercier
President and Head, U.S. Commercial, Bristol-Myers Squibb

Jill O'Donnell-Tormey
CEO and Director of Scientific Affairs, Cancer Research Institute

Antoni Ribas
Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology, University of California Los Angeles

Greg Simon
President, Biden Cancer Initiative

Published July 5, 2018